Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Capital Markets

New Horizon Health  / Equity Capital Markets

New Horizon Health is a China-based cancer diagnostics company that has filed an Application Proof to list on the HKEX. The company has innovative screening technologies for colorectal, gastric, and potentially cervical cancer. The management team is accomplished and the pre-IPO investors are experienced healthcare funds. We view the company favorably and will provide a definitive view in a future Insight closer to the actual offering.

New Horizon Health is a China-based cancer diagnostics company that has filed an Application Proof to list on the HKEX. The company has innovative screening technologies for colorectal, gastric, and potentially cervical cancer. The management team is accomplished and the pre-IPO investors are experienced healthcare funds. We view the company favorably and will provide a definitive view in a future Insight closer to the actual offering.

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

On November 10th 2020, <a href="https://www.smartkarma.com/entities/new-horizon-health-limited" target="_blank" data-smartkarma-citation="entities:31039:1" rel="noopener">New Horizon Health (NHH HK)</a> filed the application to list on the Hong Kong stock exchange. Founded in November 2015, the Company focuses on early screening and detection services for high-incidence cancer homes in China, with products covering colorectal cancer, cervical cancer, stomach cancer, lung cancer, liver cancer and other fields. Although the market prospect is very good, there are still some concerns.

On November 10th 2020, New Horizon Health (NHH HK) filed the application to list on the Hong Kong stock exchange. Founded in November 2015, the Company focuses on early screening and detection services for high-incidence cancer homes in China, with products covering colorectal cancer, cervical cancer, stomach cancer, lung cancer, liver cancer and other fields. Although the market prospect is very good, there are still some concerns.

Pre-IPO New Horizon Health (NHH.HK) - Here Are the Concerns

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

New Horizon Health, a pioneer in the colorectal cancer screening market in China, is looking to raise up to USD 300m to list via a Hong Kong listing.  NH Health provides cancer screen kits for convenient early screening targeting populations recommended for regular cancer screening. The company's approved product ColoClear has an impressive accuracy compared with peer products for colorectal cancer. In addition to the ColoClear, it also offered a more mass-market product, Pupu Tube for home-based testing. The company's product has a huge unmet market and a high barrier to entry. We believe its uniqueness as the only investable stock in the segment will make the deal interesting to investors. The company's management has a good working experience and is backed by a strong line up of international and domestic investors.

New Horizon Health, a pioneer in the colorectal cancer screening market in China, is looking to raise up to USD 300m to list via a Hong Kong listing.  NH Health provides cancer screen kits for convenient early screening targeting populations recommended for regular cancer screening. The company's approved product ColoClear has an impressive accuracy compared with peer products for colorectal cancer. In addition to the ColoClear, it also offered a more mass-market product, Pupu Tube for home-based testing. The company's product has a huge unmet market and a high barrier to entry. We believe its uniqueness as the only investable stock in the segment will make the deal interesting to investors. The company's management has a good working experience and is backed by a strong line up of international and domestic investors.

New Horizon Health (诺辉健康) Pre-IPO: A Hot Medical Device Deal in Making

China

New Horizon Health Limited operates cancer screening technology development business. The Company develops and sells colorectal cancer screening test products, gastric cancer screening test products, and other products. New Horizon Health markets its products throughout China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

New Horizon Health (6606 HK)

New Horizon IPO: Leaning Positive

New Horizon Health is a cancer diagnostics company that plans to list on the HKEX. The company has innovative tests for CRC, gastric, and...

Kemp Dolliver, CFA

Pre-IPO New Horizon Health (NHH.HK) - Here Are the Concerns

This article summarized the concerns for the New Horizon Health in terms of product commercialization, penetration rate of core products, financial...

Xinyao (Criss) Wang

New Horizon Health (诺辉健康) Pre-IPO: A Hot Medical Device Deal in Making

The company's product has a huge unmet market and a high barrier to entry. We believe its uniqueness as the only investable stock in the segment...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)